BIOMAT Database Logo BIOMAT Database Logo

Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. 1995

G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, WA 98125-7001, USA.

PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) serum levels were determined in over 235 prostate cancer patients from 8 different United States clinical urological cancer centers. The clinical data were not known until after the serum assay results were shared with all participants to attempt to eliminate possible clinical bias. PSA values are useful in the clinical diagnosis and staging of prostate cancer patients, and generally fall to low values in response to effective treatment, e.g., surgery, hormones, radiation, chemotherapy. PSMA values are not related to clinical stage but if elevated can fall in response to effective treatments. In contrast, PSMA values can be elevated post-treatment in the presence of very low PSA levels (0.01 to 0.00). The elevated PSMA levels predicted a state of clinical progression or clinical resistance in most cases (> 70%). PSMA levels in this study were of better prognostic value than PSA.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D043425 Glutamate Carboxypeptidase II A metallocarboxypeptidase that is predominantly expressed as a membrane-bound enzyme. It catalyzes the hydrolysis of an unsubstituted, C-terminal glutamyl residue, typically from PTEROYLPOLYGLUTAMIC ACIDS. It was formerly classified as EC 3.4.19.8. FOLH1 Protein,Folate Hydrolase I,N-Acetylaspartylglutamate Peptidase,N-Acetylated-alpha-Linked Acidic Dipeptidase,NAAG Peptidase,NAALADase,NAALADase II,NAALADase L,Acidic Dipeptidase, N-Acetylated-alpha-Linked,Carboxypeptidase II, Glutamate,Dipeptidase, N-Acetylated-alpha-Linked Acidic,Hydrolase I, Folate,N Acetylaspartylglutamate Peptidase,N Acetylated alpha Linked Acidic Dipeptidase,Peptidase, N-Acetylaspartylglutamate

Related Publications

G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
March 1995, The Prostate,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
July 1997, Cancer,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
October 1999, European urology,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Serum prostate-specific antigen levels in stage A1 prostatic cancer.
August 1993, American journal of clinical pathology,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
[Prostate-specific antigen and prostatic cancer].
February 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
[Prostate-specific antigen and prostatic cancer].
March 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
[Results of studies of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hypertrophy and prostatic cancer].
July 1995, Orvosi hetilap,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Prostatic specific antigen in prostate cancer.
January 1987, The International journal of biological markers,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Prostate-specific antigen in prostatic cancer.
January 1988, American journal of clinical oncology,
G Murphy, and H Ragde, and G Kenny, and R Barren, and S Erickson, and B Tjoa, and A Boynton, and E Holmes, and J Gilbaugh, and T Douglas
Prostatic specific antigen in prostate cancer.
September 1992, Urologic nursing,
Copied contents to your clipboard!